(firstQuint)Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer.

 This program is currently restricted to the United States for patients with metastatic HER2+ breast cancer for whom current HER2+ standard of care treatment has been exhausted.

 Patients may not be eligible for the HER2CLIMB trial.

 Each request for a single patient IND will be reviewed individually by the Cascadian Medical Team.

.

 Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer@highlight

Physicians interested in requesting a single patient IND should contact Cascadian Therapeutics at EAPrequest@CascadianRX.

com